Opinion|Videos|October 28, 2024
First-Line ESA vs Luspatercept in LR-MDS: Choosing the Most Appropriate Treatment Option for Each Individual Patient
Panelists discuss how their clinical experience with ESA failure rates and timelines compares with reported outcomes in large community practice studies, and how they counsel patients on the choice between luspatercept and ESAs as first-line therapy for lower-risk MDS, incorporating patient preferences and patient-reported outcomes from recent clinical trials.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please describe: In your clinical practice, what percentage of your patients have disease that fails ESA? What is the general time frame where you may see ESA failure?
- How does this compare with reported ESA outcomes? Resource link: Gordan L, et al. LR-MDS large US community practice: pt outcomes post ESA Tx. EHA 2024 abstract.
- Please describe what you typically counsel and/or share with your patients when considering luspatercept vs ESA as first-line therapy for LR-MDS. How do you take into consideration the patient’s preference
Resource link: Olivia EN, et al. Patient-reported outcomes from COMMANDS study. ASH 2023 abstract.
Advertisement
Related to this article
The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
A 3-year, $225K award will focus on improving quality of life for patients living with long-term effects of cancer treatment.
China's NMPA accepted a supplemental application expanding toripalimab's perioperative NSCLC indication to stage II-III disease.
An updated HARMONi analysis showed a consistent OS benefit with ivonescimab plus chemotherapy in EGFR-mutated NSCLC.
Faculty reviewed data-driven advances in treatment intensification, sequencing, and emerging biomarkers across the prostate cancer and RCC continuums.
Sacituzumab govitecan produced an ORR of 35% in heavily pretreated platinum-resistant ovarian cancer in a phase 2 study.
The FDA approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
Sacituzumab Govitecan Yields Responses in Platinum-Resistant Ovarian Cancer
3
Ivonescimab Plus Chemotherapy Sustains OS Benefit Across Western and Asian Patients in Pretreated EGFR-Mutated NSCLC
4
Dr Mardones on Giredestrant Plus Palbociclib in Estrogen Receptor+ Breast Cancer
5